Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction between CYP2D6, CYP3A4 and CYP1A2 and antipsychotics

Autor: Lianne Beunk, Marga Nijenhuis, Bianca Soree, Nienke J. de Boer-Veger, Anne-Marie Buunk, Henk Jan Guchelaar, Elisa J. F. Houwink, Arne Risselada, Gerard A. P. J. M. Rongen, Ron H. N. van Schaik, Jesse J. Swen, Daan Touw, Roos van Westrhenen, Vera H. M. Deneer, Jan van der Weide

Publikováno v: European Journal of Human Genetics. Nature Publishing Group
European Journal of Human Genetics. SPRINGERNATURE
European Journal of Human Genetics

The Dutch Pharmacogenetics Working Group (DPWG) aims to facilitate pharmacogenetics implementation in clinical practice by developing evidence-based guidelines to optimize pharmacotherapy. A guideline describing the gene-drug interaction between the

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::26d87804d4af6dcbaf1b5d9f3f194979
https://cris.maastrichtuniversity.nl/en/publications/8434c9e0-c985-4bc8-a492-71fb47e9fdc5

Dutch pharmacogenetics working group (DPWG) guideline for the gene–drug interaction between UGT1A1 and irinotecan

Autor: Emma C. Hulshof, Maarten J. Deenen, Marga Nijenhuis, Bianca Soree, Nienke J. de Boer-Veger, Anne-Marie Buunk, Elisa J. F. Houwink, Arne Risselada, Gerard A. P. J. M. Rongen, Ron H. N. van Schaik, Daan J. Touw, Jan van der Weide, Roos van Westrhenen, Vera H. M. Deneer, Henk-Jan Guchelaar, Jesse J. Swen

Publikováno v: European Journal of Human Genetics. SPRINGERNATURE
European Journal of Human Genetics

The Dutch Pharmacogenetics Working Group (DPWG) aims to facilitate PGx implementation by developing evidence-based pharmacogenetics guidelines to optimize pharmacotherapy. This guideline describes the starting dose optimization of the anti-cancer dru

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e8ff773659822a1efb3a684e66e58279
https://hdl.handle.net/1887/3515271

Correction: Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene–drug interaction between CYP2D6 and opioids (codeine, tramadol and oxycodone)

Autor: Maja Matic, Marga Nijenhuis, Bianca Soree, Nienke J. de Boer-Veger, Anne-Marie Buunk, Elisa J. F. Houwink, Hans Mulder, Gerard A. P. J. M. Rongen, Jan van der Weide, Bob Wilffert, Jesse J. Swen, Henk-Jan Guchelaar, Vera H. M. Deneer, Ron H. N. van Schaik

Publikováno v: Eur J Hum Genet

The current Dutch Pharmacogenetics Working Group (DPWG) guideline, describes the gene-drug interaction between CYP2D6 and the opioids codeine, tramadol and oxycodone. CYP2D6 genotype is translated into normal metaboliser (NM), intermediate metabolise

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e6930318714bbd8a3dac7c588c488077
https://europepmc.org/articles/PMC9553971/